Medical isotopes are essential tools in modern medicine, facilitating diagnostic imaging and therapeutic treatments. These isotopes, produced primarily in nuclear reactors or accelerators, enable doctors to visualize internal organs, detect diseases, and target treatments for conditions like cancer and heart disease. Technetium-99m, derived from molybdenum-99, is particularly crucial for diagnostic imaging procedures worldwide. However, ensuring a stable supply of medical isotopes remains a challenge, driving ongoing efforts to diversify production methods and enhance supply chain resilience. Join our panelists for their insights on how to address radioisotope production challenges on several levels and how they aim to incorporate isotope production into their existing infrastructure!

Panelists

  • Michael D. Heibel (Westinghouse Electric Co.)
  • John R. Massari (Constellation Generation)
  • Artem Matyskin (Penn State University - Radiation Science & Engineering Center)

Resources

To access session resources, you must be logged in and registered for the meeting.

Register NowLog In

Attachment — Isotope Production Bios

Discussion

To join the conversation, you must be logged in and registered for the meeting.

Register NowLog In